Processa Pharmaceuticals Files 8-K
Ticker: PCSA · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Processa Pharma filed an 8-K on April 11, 2024, covering Reg FD and financials.
AI Summary
On April 11, 2024, Processa Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Heatwurx, Inc., is incorporated in Delaware and headquartered in Hanover, Maryland.
Why It Matters
This 8-K filing provides important updates and disclosures for Processa Pharmaceuticals, Inc., which could impact investor understanding of the company's regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain significant negative news or events.
Key Numbers
- 001-39531 — SEC File Number (Identifies the company's filing with the SEC)
- 45-1539785 — IRS Number (Company's Employer Identification Number)
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- Heatwurx, Inc. (company) — Former company name
- April 11, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Hanover, Maryland (location) — Principal executive offices
FAQ
What specific items are covered under the Regulation FD Disclosure in this 8-K?
The filing indicates it is a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the header information.
What are the main categories of exhibits filed with this 8-K?
The filing states that Financial Statements and Exhibits are included, but the specific exhibits are not listed in the provided text.
When was Processa Pharmaceuticals, Inc. formerly known as Heatwurx, Inc.?
The date of the name change from Heatwurx, Inc. to Processa Pharmaceuticals, Inc. was October 28, 2011.
What is the principal business address of Processa Pharmaceuticals, Inc.?
The principal executive offices are located at 7380 Coca Cola Drive, Suite 106, Hanover, Maryland 21076.
What is the Standard Industrial Classification (SIC) code for Processa Pharmaceuticals, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-11 08:00:32
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 1KB
- ex99-2.htm (EX-99.2) — 1KB
- ex99-1_001.jpg (GRAPHIC) — 716KB
- ex99-2_001.jpg (GRAPHIC) — 631KB
- 0001493152-24-014278.txt ( ) — 2068KB
- pcsa-20240411.xsd (EX-101.SCH) — 3KB
- pcsa-20240411_lab.xml (EX-101.LAB) — 33KB
- pcsa-20240411_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01. Regulation Disclosure
Item 7.01. Regulation Disclosure. David Young, President, R&D for Processa Pharmaceuticals, Inc. (" Processa ") presented two abstracts at the AACR Annual Meeting 2024 including new data on the NGC Cap Phase 1b trial. The NGC-Cap preliminary data was included in the abstract and additional data was presented in the full poster. The poster presented has subsequently been modified from the version previously presented. The amended full posters have been made available in the "Publications" section on Processa's website, located at https://www.processapharmaceuticals.com and are available as Exhibit 99.1 and 99.2 attached hereto . Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the "Investors" section of Processa's website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. The information in this Item 7.01 and Exhibits 99.1 and 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. Exhibit No. Exhibit Description 99.1 Next generation capecitabine (NGC-Cap) in Phase 1b trail significantly increases 5-FU exposure while improving safety profile compared to capecitabine, April 8, 2024. 99.2 Application of Phase 1 and pre-clinical data to assist in determining the optimal dosage regimen for cancer drugs using the principals